A large array of clinically unique disease-modifying therapies (DMTs) is approved for the treatment of multiple sclerosis (MS) in the United States. Competition in this crowded market has intensified with the launch of Ocrevus and Copaxone generics, making treatment choices more complex. The U.S. market is expected to become even more competitive with the potential launch of second-generation follow-on DMTs (e.g., Novartis’s siponimod, Celgene’s ozanimod, Janssen/Acetlion’s ponesimod, Biogen’s BIIB-098) that are poised to offer incremental clinical gains over the next several years, coupled with the entry of oral generics. These evolving dynamics make brand differentiation as well as understanding of drug prescribing patterns and key patient characteristics, including financial burden, ever more critical for current and future players.
QUESTIONS ANSWERED
What is the patient share for Ocrevus, generic versions of Copaxone, orals, and other key therapies?
What are the demographic characteristics and clinical profiles of U.S. MS patients on injectables, orals, and infusions?
What are the key risk factors, comorbidities, and co-prescribed therapies by patient segment for MS?
How do MS patient cohorts compare in care utilization and outcomes (physician visits and other healthcare encounters)?
What insurance type and provider do MS patients have?
What are the reimbursed and out-of-pocket costs by brand?
PRODUCT DESCRIPTION
Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive Real World Data (RWD) repository.